Salvage Chemotherapy for Refractory Germ Cell Tumors

June 15, 2014

When relapse occurs in patients with germ cell tumors, two salvage treatment paradigms exist: standard-dose chemotherapy, or high-dose chemotherapy with autologous stem cell rescue.

Most patients with germ cell tumors will be cured with local therapy and/or standard chemotherapy. When relapse occurs, two salvage treatment paradigms exist: standard-dose chemotherapy (SDC), or high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR). Limited prospective comparative data exist to guide decision making.

At the University of Southern California (USC), it is our practice to begin by estimating the likelihood of a durable remission based on individual characteristics. Factors including pure seminoma, prior complete response (CR) to cisplatin therapy, low-volume metastases, and a testicular primary predict for cure with standard-dose salvage[1-4] and may help clinicians identify patients for whom SDC is preferred. However, it is important to consider that HDC-ASCR may be more effective in patients at first relapse, even in populations expected to respond to SDC salvage, and it may also be safer when administered earlier. For example, in a series of relapsed seminoma patients treated with HDC, 92% of patients in first relapse achieved CR, compared with 67% of those treated in the third- or fourth-line setting.[5] There have been reports of greater toxicity from ASCR in germ cell tumor patients with greater prior cisplatin exposure.[6]

SDC

Ifosfamide-based regimens

Ifosfamide-based regimens are a standard of care in the second-line setting; such regimens include TIP (paclitaxel at 250 mg/m2 by continuous infusion on day 1, ifosfamide at 1.2 g/m2 daily, and cisplatin at 20 mg/m2 daily on days 2 to 6) or VeIP (vinblastine at .11 mg/kg for 2 days plus ifosfamide and cisplatin). These regimens result in a CR rate of 36% in first-relapse patients[7] but a 70% CR rate in selected good-risk patients.[8] In seminoma patients, VeIP as first salvage yielded a CR in 83% of patients.[1] Toxicity with ifosfamide-based combination regimens is substantial, with the hospitalization rate for neutropenic fever as high as 89%.[7] We routinely use granulocyte colony-stimulating factor (G-CSF) prophylaxis during salvage treatment for patients with germ cell tumors.

Gemcitabine-based therapy

A regimen of gemcitabine at 1,000 mg/m2 on day 1 and day 8, and oxaliplatin at 130 mg/m2 on day 1 of a 21-day cycle, produced CR rates of 8% to 14% and partial response (PR) rates of 17% to 37% in 2 small prospective series.[9,10] All patients with a PR subsequently had progression, with duration of PR ranging from 2 months to 8 months. Up to 10% of patients experience grade 3 neuropathy, although in one series there was complete resolution after treatment cessation.[10] Adding paclitaxel to gemcitabine and oxaliplatin (GOT) probably improves efficacy. Bokemeyer and colleagues reported on 73 patients treated with GOT, of whom 78% had received prior HDC (half as primary treatment).[11] A total of 4 patients (5.5%) achieved CR, while 6 additional men achieved CR after resection of residual disease (total, 13.7%). Toxicity was similar to that of the doublet regimens. At USC, we designed a dose-dense form of GOT, cycled every 14 days,[12] with paclitaxel at 170 mg/m2 on day 1. We escalated the oxaliplatin dose from 100 mg/m2 in the first cycle to 125 mg/m2 in the second and subsequent cycles if the absolute neutrophil count was greater than 1,500 cells/μL and platelet counts were over 75,000/μL, and neuropathy was less than grade 2 with no infection present. We found a 6.7% CR rate, with 5 additional patients (total, 16.7%) becoming resectable, resulting in durable remission in a population with a median of 2 prior lines of therapy. This has become our standard salvage regimen for patients in whom second line cisplatin-ifosfamide combinations fail and/or who are not candidates for HDC stem-cell therapy.

HDC With ASCR

The efficacy of HDC-ASCR in germ cell tumor patients at first relapse or with primary refractory germ cell tumors is controversial. Our approach to these patients incorporates the risk-stratification system outlined by the International Prognostic Factors Study Group (IPFSG).[13] After studying 1,594 patients with relapsed germ cell tumors who progressed after more than 3 cycles of first-line cisplatin-based therapy, multivariate analysis identified histology, primary tumor location, response, and progression-free interval from first therapy; alpha-fetoprotein and human chorionic gonadotropin levels; and presence of liver, bone, or brain metastasis as independent prognostic factors (see Table).

There are five prognostic groups, beginning with very-low-risk patients (−1 point), who had an overall survival (OS) rate at 5 years of 77%, and ending with a very-high-risk group (3 points), whose 5-year OS was 6.1%. Our practice is to offer HDC-ASCR to patients unlikely to be cured by SDC: those in the (very) high-risk IPFSG groups (with scores of 2 or 3 points), and selected intermediate-risk patients (with a score of 1 point). We offer HDC-ASCR to all patients at second relapse, based on single-arm studies demonstrating long-term survival in this setting.[14,15]

Despite the lack of prospective randomized data favoring HDC over SDC in first relapse, retrospective data suggest that HDC with tandem ASCR may be preferable. In a retrospective analysis of the IPFSG database, 821 patients who received HDC as first salvage treatment were compared with 773 patients who received SDC. Although bias may confound the results, 2-year event-free survival was significantly better with HDC than with SDC (55% vs 44.1%, P <.001) in all 5 risk groups, and there was an overall survival advantage (60.6% vs 46.3%, P < .001) except for patients in the lowest risk groups.[16]

We generally exclude patients with (very) low-risk prognosis (0–1 point) from HDC in first relapse based on the lack of OS benefit identified in the IPFSG study, and on the efficacy of TIP in these patients. Of note, patients in the very-low-risk group in the IPFSG study showed a 40% event-free survival when treated with SDC, which is significantly lower than the rate seen with HDC. However, the OS was similar, indicating that salvage therapies were effective in this subset. The intermediate-risk group (1 point) experienced a 31% event-free survival at 2 years and a 45% OS at 5 years with SDC, with a statistical difference favoring HDC. Thus, our practice is to strongly consider intermediate-risk patients for HDC, especially those with high levels of tumor markers or early relapse. Initial HDC salvage therapy for patients with primary mediastinal disease was not believed to be beneficial in the Indiana experience,[17] although some durable remissions were seen in these patients using the TI-CE regimen (paclitaxel, ifosfamide induction followed by high-dose carboplatin, etoposide).[18]

Definitive recommendations cannot be made until additional randomized studies are completed. The single prospective randomized study that compared HDC (VIP [cisplatin, ifosfamide, etoposide]/VeIP × 3 cycles with single HDC-ASCR) to SDC (VIP/VeIP × 4 cycles) in first relapse did not show an event-free survival or OS advantage.[19] However, this study has been criticized because a large number of patients did not receive the intended HDC, and because single HDC-ASCR was utilized, which has been associated with inferior outcomes compared with tandem transplant approaches.[20] We favor tandem high-dose treatment with stem cell rescue following the TI-CE regimen published by Motzer and colleagues.[18]

Conclusions

For patients experiencing their first relapse of seminoma, and other patients whose IPFSG scores classify them as low risk, SDC is a reasonable choice for salvage treatment. For those whose IPFSG scores classify them as intermediate to very high risk, our preferred treatment is HDC-ASCR, and we offer HDC-ASCR to all SDC-pretreated patients at second relapse. Resection of residual disease is an important consideration and contributes to cure even in heavily pretreated patients.[21] An intensified GOT regimen can yield a CR even in patients with highly refractory disease, including those who relapse after transplant.

Financial Disclosure:The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

References:

1. Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15:1427-31.

2. Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-89). Cancer. 1991;67:1305-10.

3. Pizzocaro G, Salvioni R, Piva L, et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ cell tumors. Long-term results. Ann Oncol. 1992;3:211-6.

4. Loehrer P, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470-6.

5. Agarwala AK, Perkins SM, Abonour R, et al. Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol. 2011;34:286-8.

6. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol. 1996;14:1098-105.

7. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin- containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15:2559-63.

8. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000; 18:2413-18.

9. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin refractory germ cell tumors: a phase II study. Annals Onc. 2004;15:493-7.

10. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108-14.

11. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19:448-53.

12. Quinn DI, Hamid O, Tsao-Wei D, et al. Gemcitabine, oxaliplatin and paclitaxel (GOT) on a 2-2-weekly schedule in patients with refractory germ cell carcinoma: a phase II study conducted at the University of Southern California. Ann Oncol. 2012;23(suppl):abstr 790.

13. The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906-11.

14. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340-8.

15. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706-13.

16. Lorch A, Bacoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178-84.

17. Suleiman Y, Siddiqui BK, Brames MJ, et al. Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors. Biol Blood Marrow Transpl. 2013;19:161-3.

18. Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2006;25:85-90.

19. Pico J-L, Rosti G, Kramar A, et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol. 2005;16:1152-9.

20. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800-5.

21. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324-9.